Search Results
MEDICARE ISSUES PROPOSED COVERAGE DECISION ON ERYTHROPOESIS STIMULATING AGENTS
The Centers for Medicare & Medicaid Services (CMS) announced today its proposed decision to limit coverage of erythropoiesis stimulating agent (ESA) treatment for beneficiaries with certain cancers and related neoplastic conditions, either because of a deleterious effect of the ESA on the beneficiaries’ underlying disease or because the underlying disease increases their risk of adverse effects related to ESA use.
Press Release CMS ANNOUNCES DEMONSTRATION PROJECTS TO REDUCE DISPARITIES IN CANCER PREVENTION AND TREATMENT
Press Release